N-PORT filing recap · January 2023
What did ARK Genomic Revolution ETF buy in January 2023?
Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.
Stock value
$2.24B
Positions
45
Estimated turnover
15.1%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Increased positions
TDOCTeladoc Health, Inc.$112.45Mreported value+192.4K shares+5.3%CDNACaredx, Inc.$95.53Mreported value+250.4K shares+4.1%SDGRSchrodinger, Inc.$94.97Mreported value+246.9K shares+6.7%BEAMBeam Therapeutics Inc.$92.26Mreported value+153.0K shares+7.8%DNAGinkgo Bioworks Holdings, Inc.$86.27Mreported value+5.39M shares+13.9%ADPTAdaptive Biotechnologies Corporation$85.78Mreported value+165.6K shares+1.8%TWSTTwist Bioscience Corporation$83.14Mreported value+545.4K shares+23.2%NTLAIntellia Therapeutics, Inc.$78.97Mreported value+140.2K shares+8.2%VERVVerve Therapeutics, Inc.$63.19Mreported value+414.1K shares+17.5%SLGCUSDSomalogic Inc$37.76Mreported value+1.74M shares+19.1%MASS908 Devices Inc.$34.10Mreported value+44.0K shares+1.2%CDXSCodexis, Inc.$26.55Mreported value+225.5K shares+5.5%QSIQuantum-Si Inc$26.11Mreported value+969.3K shares+9.0%PRMEPrime Medicine, Inc.$25.07Mreported value+169.6K shares+13.5%CMPSCompass Pathways Plc$22.24Mreported value+1.10M shares+104.6%NVTAInvitae Corp$18.65Mreported value+2.62M shares+49.5%CERSCerus Corporation$18.05Mreported value+1.90M shares+49.4%PSNLPersonalis, Inc.$13.31Mreported value+397.0K shares+7.5%